

Table 1. Demographic features of adult and pediatric patients with AE- AML.

Characteristic	Adults n=98(%)	Children n=75(%)	P-value
Sex			0.277
Male	56(57.1)	49(65.3)	
Female	42(42.9)	26(34.7)	
Diagnosis			0.005
AML-M2	91(92.9)	62(82.7)	
Non-AML-M2	7(7.1)	13(17.3)	
EML	29(29.6)	10(13.3)	0.011
WBC×10 <sup>9</sup> /L	14.7(1.7-79.9)	19.3(0.1-185.0)	0.110
CD34 positive	81/88(92.0)	54/61(88.5)	0.469
CD33 positive	70/88(79.5)	52/61(85.2)	0.374
CD13 positive	77/88(87.5)	52/61(85.2)	0.691
CD117 positive	80/88(90.9)	57/61(93.4)	0.576
HLA-DR positive	76/88(86.4)	55/61(90.2)	0.484
CD19 positive	28/88(31.8)	25/61(41.0)	0.250
CD56 positive	54/88(61.4)	29/61(47.5)	0.095
Chromosome			0.416
t(8;21)	40/78(51.3)	40/69(58.0)	
With ACAs	38/78(48.7)	29/69(42.0)	
Lose of sex chromosome	29/78(37.2)	17/69(24.6)	0.102
C-KIT mutation	30/74(40.5)	12/68(17.6)	0.003
FIT3/ITD mutation	6/74(8.1)	7/68(10.3)	0.652
NPM1 mutation	3/74(4.1)	0	0.093
Induction regimens			<0.001
AA*	89/95(93.7)	14/75(18.7)	
FLAG+IDA/DAE	0	54/75(72.0)	
The others	6/95(6.3)	7/75(9.3)	
Consolidation regimens			0.011

SDAC-based	36/86(41.9)	17/74(23.0)	
MDAC-based	50/86(58.1)	57/74(77.0)	
Allo-HSCT	19/95(20.0)	10/75(13.3)	0.251
Cumulative CR rate after two courses of induction	82/95(86.3)	73/75(97.3)	0.012
Cumulative death	43/95(45.3)	15/75(20.0)	0.001
Cumulative relapse	37/86(43.0)	18/74(24.3)	0.013

---

AML, acute myeloid leukemia; EML, extramedullary leukemia; CNSL, central nervous system leukemia; WBC, white blood cell; ACAs, additional chromosomal abnormalities; WT, wild type; AA, Anthracyclines combined with cytarabine; FLAG, fludalabin, cytarabine and G-CSF; DAE, DA combined with etoposide; SDAC, standard dose cytarabine; MDAC, median dose cytarabine; Allo-HSCT, allogeneic hematopoietic stem cell transplantation; CR, complete response.

\*Anthracyclines including daunorubicin (n=34), idarubicin (n=37), mitoxantrone (n=10), pirarubicin (n=12) and homoharringtonine (n=10).